Carregant...
Evaluating the administration costs of biologic drugs: development of a cost algorithm
Biologic drugs, as with all other medical technologies, are subject to a number of regulatory, marketing, reimbursement (financing) and other demand-restricting hurdles applied by healthcare payers. One example is the routine use of cost-effectiveness analyses or health technology assessments to det...
Guardat en:
| Publicat a: | Health Econ Rev |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Berlin Heidelberg
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4883988/ https://ncbi.nlm.nih.gov/pubmed/26208926 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13561-014-0026-2 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|